Welcome to the all-new Vetlearn

  • Vetlearn is getting a new home. Starting this fall,
    Vetlearn becomes part of the NAVC VetFolio family.

    You'll have access to the entire Compendium and
    Veterinary Technician archives and get to explore
    even more ways to learn and earn CE by becoming
    a VetFolio subscriber. Subscriber benefits:
  • Over 500 hours of interactive CE Videos
  • An engaging new Community for tough cases
    and networking
  • Three years of NAVC Conference Proceedings
  • All-new articles (CE and other topics) for the entire
    healthcare team

To access Vetlearn, you must first sign in or register.


  • Registration for new subscribers will open in August 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Compendium October 2004 (Vol 26, No 10)

Cardiopulmonary Cerebral Resuscitation: Emergency Drugs and Postresuscitative Care

by Sarah Haldane, BVSc, MACVSc, Steven L. Marks, BVSc, MS, MRCVS, DACVIM (Small Animal Internal Medicine)


    Cardiopulmonary cerebral resuscitation (CPCR) is an important component of emergency and critical care medicine. Once the basic techniques of CPCR have been instituted, advanced techniques can be used to help resuscitate patients. This article discusses emergency drugs, routes of administration, and postresuscitative care.

    Once the basic techniques (i.e., "ABCs" [airway, breathing, circulation]) of cardiopulmonary cerebral resuscitation (CPCR) have been initiated, further intervention is usually indicated. This article discusses the advanced directives of CPCR, such as drug administration, fluid therapy, electrocardiography (ECG), and defibrillation. If CPCR results in successful return of spontaneous circulation (ROSC), efforts must then be directed at postresuscitative care.


    In veterinary medicine, the most commonly reported arrhythmias in cardiopulmonary arrest (CPA) are asystole, pulseless electrical activity (PEA), and ventricular fibrillation.1,2 Sinus bradycardia, sinus tachycardia, and ventricular tachycardia are frequent pre- or postarrest rhythms.1

    Ventricular asystole is seen with end-stage cardiac, pulmonary, or multisystemic disease. Increased vagal tone may also precipitate arrest characterized by ventricular asystole. Asystole has a poor prognosis for resuscitation. When indicated, rapid and aggressive CPCR and epinephrine administration should be instituted.3 Vasopressin may also be indicated if patients are refractory to epinephrine.4 When asystole is stimulated by excessive vagal tone, atropine administration may be useful.

    PEA (Figure 1), previously known as electromechanical dissociation, occurs when there is no myocardial contractility despite a normal heart rate and rhythm during ECG. PEA may be the terminal rhythm in patients with metabolic or cardiac disease, and the prognosis for successful resuscitation is poor.5 PEA may also result from hypovolemia, cardiac tamponade, or pleural space disease, and the prognosis improves if the underlying cause can be rapidly corrected. Epinephrine administration is currently recommended in treating PEA,3 and efforts should be directed at stabilizing blood volume, oxygenation, ventilation, and circulation. Atropine,6-8 calcium chloride,8 calcium channel blockers,9 and naloxone10 have all been evaluated for use in PEA. Although experimental trials with atropine administration or vagotomy have been shown to improve the rate of ROSC,7,11 none of these drugs has consistently been shown to be useful in the clinical situation.

    Ventricular fibrillation (Figure 2) is seen in 30% to 60% of humans12,13 and approximately 20% of animals that experience CPA.1,2 Fibrillation results in random electrical stimulation to the myocardium so that the ventricles are unable to effectively contract. Early intervention with electrical defibrillation is the treatment of choice.3,14,15 Electrical defibrillation involves administering a direct current, applied externally or internally. For external defibrillation, the contact areas are optimally on either side of the thoracic cavity, although in large deep-chested dogs, the paddles may be placed in dorsal and ventral positions on the same side of the chest. The contact areas should be clipped and gel applied to the defibrillator electrodes. A charge of 3 to 5 J/kg may be applied.14 Internal defibrillation requires an electric shock applied directly to the heart. Internal defibrillator paddles may be wrapped in saline-soaked gauze and applied on either side of the heart. A charge of 0.5 to 1 J/kg may be applied.14

    For both internal and external defibrillation, three shocks can be given in succession, with only a short pause to recharge the defibrillator and check the ECG tracing between each shock.16 The charge administered may be doubled if two shocks have not resulted in conversion to a sinus rhythm.14,17 If defibrillation is not successful, chest compressions should be resumed for 1 to 2 minutes before reapplying a charge. Care should be taken during defibrillation to ensure that personnel are not in contact with the animal or table and that there are not excessive quantities of alcohol around the external contact areas.14

    Fibrillation lasting longer than 5 minutes is very difficult to convert with electrical defibrillation, although success rates may be improved by providing cardiac compressions and ventilation to enhance myocardial blood flow before electrical defibrillation.17 Epinephrine can improve coronary perfusion pressure and may change fine fibrillation to coarse fibrillation, which is easier to convert with electrical defibrillation.15,17 However, epinephrine also increases myocardial oxygen demand and, in turn, may increase the risk of myocardial ischemia and postresuscitative arrhythmia.

    In most cases, there is no indication to use antiarrhythmic therapy to treat sinus tachycardia. The cause of tachycardia should be evaluated and treated when possible. Sinus tachycardia may be caused by fear, excitement, pain, fever, hypovolemia, hypoxemia, increased sympathetic stimulation, and many disease states.

    Ventricular tachycardia has been defined as three or more rapid, successive, ventricular premature depolarizations or as a continuous series of ventricular beats for more than 30 seconds.18 It can be caused by both cardiac and noncardiac disease. Treatment should be aimed at the underlying cause. Antiarrhythmic therapy is indicated only if ventricular tachycardia is severe (i.e., a sustained heart rate >200 bpm or R on T phenomenon seen on ECG) or there is evidence of circulatory compromise (i.e., pale mucous membranes, weakness, syncope, peripheral pulse rate <60 bpm). Lidocaine administration may be indicated for sustained ventricular tachycardia.18

    Hypothermia, increased vagal tone, anesthesia, and certain drugs may cause sinus bradycardia. If bradycardia continues despite resolution of the underlying cause, the treatment of choice is atropine. Epinephrine or dopamine may also be effective in this situation.


    Many drugs have been evaluated for use in CPCR (Table 1), but very few have been proven to have efficacy during CPA. Epinephrine remains the first-line drug for treating bradyarrhythmia, asystole, ventricular fibrillation, or hypotension during CPA.3 Epinephrine is an adrenergic agonist agent with effects at both a- and b-adrenergic receptors. In CPCR, the a-adrenergic effects are the most useful, causing intense peripheral vasoconstriction that leads to increased mean arterial blood pressure, increased aortic diastolic pressure, and therefore increased coronary perfusion pressure. b-Adrenergic stimulation increases the heart rate and myocardial contractility and improves cerebral perfusion by vasodilating the cerebral vasculature, whereas a-agonists mediate constriction of the extracerebral carotid vessels.19-21 Other b-adrenergic effects are potentially less helpful because the positive inotropic effects may potentiate arrhythmias and increase the oxygen demand within the myocardium and cerebrum. However, studies have shown that standard-dose epinephrine has equal or increased survival-to-discharge rates compared with pure a-agonists or epinephrine combined with b-blockers.21,22

    Historically, low-dose epinephrine (i.e., 0.01 to 0.02 mg/kg) has been administered to patients in which CPCR has been performed. High-dose epinephrine (i.e., 0.2 mg/kg) was shown to increase myocardial and cerebral perfusion as well as oxygen extraction and initial ROSC in human clinical trials.23 However, there has also been an increased incidence of postresuscitative complications, such as hyperglycemia, hyperkalemia, cardiac dysrhythmias, and myocardial necrosis, with administration of high-dose epinephrine, with no change or even a decrease in 24-hour survival rates.22,24 High-dose epinephrine is currently not recommended for routine use in CPCR but may be indicated if lower doses fail to achieve ROSC.3

    Vasopressin is a nonadrenergic hormone that de­creases renal blood flow and urine output and, in slightly higher doses, stimulates the smooth muscle of precapillary arterioles, causing vasoconstriction in the peripheral tissue beds.25 It increases myocardial and cerebral blood flow without the positive inotropic and chronotropic effects of epinephrine.25 Vasopressin has a longer onset of action than epinephrine and a long half-life (17 to 35 minutes) in circulation. Exogenous vasopressin administration has been shown to have a bene­ficial effect on ROSC in human and porcine ex­perimental trials26"29 and an outcome similar to that of epinephrine in clinical trials.4,26 It has been suggested that vasopressin may be more useful than epinephrine in asystolic cardiac arrest.4 However, there are concerns that its prolonged duration of action may cause post-CPA complications regarding ongoing vasoconstriction and significantly decreased renal blood flow.25

    Atropine sulfate has parasympatholytic (vagolytic) effects and is recommended in treating sinus bradycardia or counteracting effects of increased vagal tone. It has also been used in combination with epinephrine to treat ventricular asystole and PEA6,7; in clinical trials, however, atropine has not been shown to increase survival or ROSC.8,30

    Bretylium tosylate is a class 3 antiarrhythmic agent regarded as a chemical defibrillator; used alone, however, it is unlikely to convert ventricular fibrillation in dogs. Using bretylium may decrease the amount of electrical charge required for defibrillation.31 Bretylium decreases norepinephrine release from peripheral adrenergic nerve endings, leading to antiadrenergic and hypotensive effects. Loss of autonomic reflexes may result in impaired recovery of patients from episodes of defibrillation32; thus this drug is not widely used in veterinary medicine. Bretylium is not currently recommended for use in human CPCR because of its variable efficacy, side effects, and limited availability.3

    Other drugs have been advocated for managing refractory ventricular fibrillation. Amiodarone is another class 3 antiarrhythmic agent recommended for preventing fibrillation and increasing the success of electrical defibrillation. Amiodarone has been used in humans to treat ventricular fibrillation and in dogs to treat refractory ventricular tachycardia.33,34 It may prevent potassium efflux from myocytes secondary to prolonged global ischemia and therefore prevent development of terminal arrhythmia.35 Hypomagnesemia has been associated with myocardial Purkinje fiber excitability and consequently with generation of ventricular arrhythmia.36 Infusion of magnesium chloride has been used to convert refractory ventricular dysrhythmia to a normal sinus rhythm. Magnesium administration may also decrease ischemic brain injury and interfere with calcium-mediated reperfusion injury by blocking calcium-dependent membrane channels.36"38

    Lidocaine is not indicated for ventricular fibrillation because it may increase the defibrillation threshold and make electrical defibrillation more difficult.39,40 Lidocaine may be indicated for postarrest ventricular tachycardia, although amiodarone or procainamide has recently been advocated as a first-line drug in these ­situations.3,18

    Naloxone is an opiate antagonist. Although usually given to counteract the cardiodepressant and sedative effects of exogenously administered narcotics, naloxone can also counter the myocardial effects of endogenous opiates. Endogenous opioids are thought to play a role in depressing myocardial contractility, possibly leading to generation of PEA. Naloxone may also have mild direct vasoconstrictive, antiarrhythmic, and positive inotropic effects.41 In CPCR, it has been administered to reverse opiate effects and make the myocardium more responsive to catecholamines; however, there is no increase in myocardial blood flow, cerebral perfusion, or survival with naloxone administration.10,41

    In hypoxic states, calcium entry into cells may increase. Increased intracellular calcium can lead to uncoupling of oxidative phosphorylation and generation of inflammatory mediators and oxygen free radicals, which are toxic to brain tissue. Increased intracellular calcium has also been implicated in myocardial stunning, in which myocardial cells surrounding a zone of ischemia become dormant, leading to an increased propensity for cardiac arrhythmia.42 Administering calcium to patients in CPA is not recommended by the American Heart Association unless there is documented hypocalcemia, hyperkalemia, or hypermagnesemia or there has been a calcium channel blocker overdose.3

    Calcium channel blockers may act on the ischemic myocardium to increase blood flow and raise the threshold of ventricular fibrillation. They may also antagonize the proarrhythmogenic effects of b-adrenergic stimulation following ischemic events and exogenous epinephrine administration. By blocking calcium-mediated reperfusion injury, calcium channel blockers may also improve neurologic recovery after return of spontaneous cerebral blood flow.9,43

    In low-flow circulatory states, carbon dioxide (CO2) accumulates in peripheral vascular beds. Hypercarbia leads to decreased left ventricular performance, decreased cardiac output, and increased refractoriness of myocardial cells. In this situation, acidemia can be resolved by reinstituting pulmonary blood flow, which facilitates excretion of accrued CO2 via the respiratory system. When high levels of CO2 are present in the blood, administering sodium bicarbonate (NaHCO3) paradoxically worsens intracellular and cerebral acidosis by further increasing CO2 levels via the carbonic anhydrase reaction. Adverse effects of NaHCO3 administration include hypernatremia, hypokalemia, decreased ionized calcium concentrations, and increased incidence of cardiac arrhythmia. Overdosing NaHCO3 leads to metabolic alkalosis, which, in turn, causes a left shift in the oxyhemoglobin dissociation curve. This means there is less offloading of oxygen from red cells in the peripheral tissues and, consequently, cellular hypoxia is exacerbated.44,45 However, if venous blood gas measurements reveal preexisting metabolic acidosis, NaHCO3 administration may be indicated.

    Glucose administration is not advised during CPCR because studies have shown increased morbidity and mortality associated with hyperglycemia in patients that have experienced CPA. Glucose is a substrate for anaerobic glycolysis and lactic acid production. In brain tissue, toxic concentrations of lactic acid accumulate and cause cellular damage, leading to permanent neurologic dysfunction.46,47

    Route of Administration

    The route of choice for administering drugs during CPCR is via a jugular catheter to allow simultaneous fluid and drug administration, facilitate delivery of drugs at their site of action, and decrease the possibility of extravasation of vasoactive drugs, which may cause tissue necrosis. Using a hindlimb catheter is not recommended because flow to and from the caudal half of the body is restricted during CPCR. If an intravenous catheter is not in place before CPA, intravascular access may be difficult to attain and a venous cutdown may be required. Some emergency drugs can be administered via the intratracheal route (e.g., lidocaine, epinephrine, atropine, naloxone, vasopressin) at higher doses than are usually given intravenously (Table 1). A 5- to 8-Fr urinary catheter or feeding tube may be used to deposit the drugs, diluted with sterile saline, into the small airways (Figure 3). Immediately applying positive-pressure ventilation enhances drug absorption.3 The efficacy of this practice was recently questioned by two human studies in which endotracheal administration of medications during CPCR was associated with a lower ROSC48 and survival to discharge49 compared with intravenous administration. These results may have been confounded by significant comorbidity in patients with difficult venous access; however, in a clinical CPCR trial in which epinephrine administration was randomly assigned to the intravenous or endotracheal route, the endotracheal route failed to significantly increase plasma epinephrine concentrations.50 Intraosseous access allows administration of both drugs and fluids.51,52 The marrow is close to the central circulation and does not collapse in cases of poor perfusion. The sites for intramedullary access include the femur, humerus, and tibia. Intracardiac administration of drugs is not recommended, especially in external CPCR, because of a high probability of injecting them into the myocardial muscle layer. This can result in hemorrhage, focal myocardial ischemia, and cardiac arrhythmia.53

    Fluid Therapy

    CPA has been shown to cause a fluid shift where the plasma volume moves from the intravascular to extra­vascular space.54,55 Judicious administration of an isotonic crystalloid or colloid may be indicated in CPCR, especially if the animal was hypovolemic before arrest. However, administering high rates of fluids can be harmful because volume loading increases right atrial pressure, possibly leading to decreased coronary perfusion pressure. Intracranial pressure may also increase, causing decreased cerebral perfusion pressure.56-58 If fluid administration is indicated, hypertonic saline has recently been reported to be more useful than normal saline or synthetic colloids in resuscitating pigs after prolonged fibrillation.59 Hypertonic saline improves intravascular volume by increasing osmotic pressure and may also prevent endothelial cell swelling, which is a common sequela to cellular hypoxia. Swollen endothelial cells cause increased resistance in the coronary and cerebral arteries, thereby decreasing blood flow and exacerbating myocardial and cerebral ischemia.59,60 Hypertonic saline should not be administered to dehydrated patients because its mechanism of action results in further intracellular fluid loss. Concurrently administering crystalloid fluids is recommended.


    Once spontaneous circulation and heartbeat have been restored, it is important to adequately monitor and support the vital organ systems, with particular emphasis on the respiratory, cardiovascular, and neurologic systems. Almost half of postresuscitation deaths in humans occur within 24 hours of CPCR.3 Postarrest inflammatory processes, reoxygenation injury, and reperfusion failure can combine to cause metabolic derangements and cellular death, which can cause organ dysfunction up to 1 to 3 days after the initial insult.3

    Supplemental oxygen administration is recommended via oxygen cage, hood, or nasal catheter. Continued ventilatory support may be required, especially if spontaneous respiration is inadequate; however, care must be taken not to overventilate the patient because postresuscitation hypocapnia may cause cerebral vasoconstriction and worsen cerebral ischemia.61 Pulmonary edema may develop secondary to positive-pressure ventilation, thoracic compressions, and changes in pulmonary hydrostatic pressure.62

    Restoring blood volume with judicious fluid therapy is indicated to counteract fluid shifts54 and treat electrolyte imbalances that occur during CPA.35 Positive inotropic support, such as dopamine or dobutamine infusion, may be required to improve cardiac output and peripheral perfusion.3

    Neurologic dysfunction is a common but often temporary postarrest complication, and a minimum of 24 to 48 hours should be allowed to elapse before basing a prognosis on neurologic signs.2 In humans, complete recovery has occurred as much as 90 days after CPCR.43,63 Mannitol infusion may be used to counteract cerebral edema and provide some scavenging of reactive oxygen species.64 Glucocorticoids are not indicated in this situation because they do not reduce cerebral edema43 and may worsen postischemic neurologic injury by increasing serum glucose levels.47 Animals with mild hypothermia (>95°F [>35°C]) after CPA should not be aggressively rewarmed because mild hypothermia combined with vascular support to maintain blood pressure may improve cerebral resuscitation.65 There are currently no recommendations to actively cool normothermic patients.3


    It is important to remember that CPCR is usually not successful and good client communication is essential to prevent unrealistic expectations for patients at risk of CPA. Successful CPCR relies on patient selection, teamwork, and appropriate use of resuscitation techniques and drugs. Having a well-trained staff and adequately stocked emergency kit significantly improve the ability to provide lifesaving care to patients.

    Downloadable PDF

    1. Rush JE, Wingfield WE: Recognition and frequency of dysrhythmias during cardiopulmonary arrest. JAVMA 200:1932-1937, 1992.

    2. Waldrop JE, Rozanski EA, Swanke ED, et al: Causes of cardiopulmonary arrest, resuscitation management and functional outcome in dogs and cats surviving cardiopulmonary arrest. J Vet Emerg Crit Care 14:22-29, 2004.

    3. American Heart Association: Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 102:I1-I384, 2000.

    4. Wenzel V, Krismer A, Arntz HR, et al: A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 350:105-113, 2004.

    5. Herlitz J, Estrom L, Wennerblom B, et al: Survival among patients with out-of-hospital cardiac arrest found in electromechanical dissociation. Resuscitation 29:97-106, 1995.

    6. DeBehnke DJ, Swart GL, Spreng D, Aufderheide TP: Standard and higher doses of atropine in a canine model of pulseless electrical activity. Acad Emerg Med 2:1034-1041, 1995.

    7. Blecic S, Chaskis C, Vincent JL: Atropine administration in experimental electromechanical dissociation. Am J Emerg Med 10:515-518, 1992.

    8. Redding JS, Haynes RR, Thomas JD: Drug therapy in resuscitation from electromechanical dissociation. Crit Care Med 11:681-684, 1983.

    9. Martin GB: Use of calcium blockers in electromechanical dissociation. Ann Emerg Med 13:846-848, 1984.

    10. Rothstein RJ, Niemann JT, Rennie 3rd CJ, et al: Use of naloxone during cardiac arrest and CPR: Potential adjunct for postcountershock electrical-mechanical dissociation. Ann Emerg Med 14:198-203, 1985.

    11. DeBehnke DJ: Effects of vagal tone on resuscitation from experimental electromechanical dissociation. Ann Emerg Med 22:1789-1794, 1993.

    12. Pottle A, Bullock I, Thomas J, Scott L: Survival to discharge following open chest cardiac compression (OCCC). A 4-year retrospective audit in a cardiothoracic specialist centre—Royal Brompton and Harefield NHS Trust, United Kingdom. Resuscitation 52:269-272, 2002.

    13. Gwinnutt CL, Columb M, Harris R: Outcome after cardiac arrest in adults in UK hospitals: Effect of the 1997 guidelines. Resuscitation 47:125-135, 2000.

    14. Cole SG, Otto CM, Hughes D: Cardiopulmonary cerebral resuscitation in small animals: A clinical practice review, Part II. J Vet Emerg Crit Care 13:13-23, 2003.

    15. Hargarten KM, Stueven HA, Waite EM, et al: Prehospital experience with defibrillation of coarse ventricular fibrillation: A ten-year review. Ann Emerg Med 19:157-162, 1990.

    16. Yu T, Weil MH, Tang W, et al: Adverse outcomes of interrupted precordial compression during automated defibrillation. Circulation 106:368-372, 2002.

    17. Weisfeldt ML, Becker LB: Resuscitation after cardiac arrest: A 3-phase time-sensitive model. JAMA 288:3035-3038, 2002.

    18. Trappe HJ, Brandts B, Weismueller P: Arrhythmias in the intensive care patient. Curr Opin Crit Care 9:345-355, 2003.

    19. Otto CW, Yakaitis RW, Blitt CD: Mechanism of action of epinephrine in resuscitation from asphyxial arrest. Crit Care Med 9:321-324, 1981.

    20. Michael JR, Guerci AD, Koehler RC, et al: Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 69:822-835, 1984.

    21. Paradis NA: Is a pressor necessary during aortic perfusion and oxygenation therapy of cardiac arrest? Ann Emerg Med 34:697-702, 1999.

    22. Hilwig RW, Kern KB, Berg RA, et al: Catecholamines in cardiac arrest: Role of alpha agonists, beta-adrenergic blockers and high-dose epinephrine. Resuscitation 47:203-208, 2000.

    23. Barton C, Callaham M: High-dose epinephrine improves the return of spontaneous circulation rates in human victims of cardiac arrest. Ann Emerg Med 20:722-725, 1991.

    24. Brown CG, Martin DR, Pepe PE, et al: A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. N Engl J Med 327:1051-1055, 1992.

    25. Pellis T, Weil MH, Tang W, et al: Evidence favoring the use of an alpha2-selective vasopressor for cardiopulmonary resuscitation. Circulation 108:2716-2721, 2003.

    26. Wenzel V, Lindner KH: Arginine vasopressin during cardiopulmonary resuscitation: Laboratory evidence, clinical experience and recommendations and a view to the future. Crit Care Med 30:S157-S161, 2002.

    27. Stadlbauer KH, Wagner-Berger HG, Wenzel V, et al: Survival with full neurologic recovery after prolonged cardiopulmonary resuscitation with a combination of vasopressin and epinephrine in pigs. Anesth Analg 96:1743-1749, 2003.

    28. Loeckinger A, Kleinsasser A, Wenzel V, et al: Pulmonary gas exchange after cardiopulmonary resuscitation with either vasopressin or epinephrine. Crit Care Med 30:2059-2062, 2002.

    29. Voelkel WG, Lurie KG, McKnite S, et al: Effects of epinephrine and vasopressin in a piglet model of prolonged ventricular fibrillation and cardiopulmonary resuscitation. Crit Care Med 30:957-962, 2002.

    30. Herlitz J, Bang A, Gunnarsson J, et al: Factors associated with survival to hospital discharge among patients hospitalized alive after out of hospital cardiac arrest: Change in outcome over 20 years in the community of Goteborg, Sweden. Heart 89:25-30, 2003.

    31. Tacker WA, Niebauer MJ, Babbs CF, et al: The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med 8:177-180, 1980.

    32. Kerber RE, Pandian NG, Jensen SR, et al: Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: Experimental studies. J Am Coll Cardiol 7:397-405, 1986.

    33. Williams ML, Woelfel A, Cascio WE, et al: Intravenous amiodarone during prolonged resuscitation from cardiac arrest. Ann Intern Med 110:839-842, 1989.

    34. Kudenchuk PJ, Cobb LA, Copass MK, et al: Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 341:871-878, 1999.

    35. Niemann JT, Cairns CB: Hyperkalemia and ionized hypocalcemia during cardiac arrest and resuscitation: Possible culprits for postcountershock arrhythmias? Ann Emerg Med 342-, 1999.

    36. Cannon LA, Heiselman DE, Dougherty JM, Jones J: Magnesium levels in cardiac arrest victims: Relationship between magnesium levels and successful resuscitation. Ann Emerg Med 16:1195-1199, 1987.

    37. Zhang Y, Davies LR, Martin SM, et al: Magnesium reduces free radical concentration and preserves left ventricular function after direct current shocks. Resuscitation 56:199-206, 2003.

    38. Tobey RC, Birnbaum GA, Allegra JR, et al: Successful resuscitation and neurologic recovery from refractory ventricular fibrillation after magnesium sulfate administration. Ann Emerg Med 21:92-96, 1992.

    39. Dorian P, Fain ES, Davy JM, Winkle RA: Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol 8:327-332, 1986.

    40. Echt DS, Gremillion ST, Lee JT, et al: Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol 5:752-760, 1994.

    41. Gervais HW, Eberle B, Hennes HJ, et al: High dose naloxone does not improve cerebral or myocardial blood flow during cardiopulmonary resuscitation in pigs. Resuscitation 34:255-261, 1997.

    42. Stueven HA, Thompson BM, Aprahamian C, Tonsfeldt DJ: Calcium chloride: Reassessment of use in asystole. Ann Emerg Med 13:820-822, 1984.

    43. Bass E: Cardiopulmonary arrest: Pathophysiology and neurologic complications. Ann Intern Med 103:920-927, 1985.

    44. Kette F, Weil MH, von Planta M, et al: Buffer agents do not reverse intramyocardial acidosis during cardiac resuscitation. Circulation 81:1660-1666, 1990.

    45. Guerci AD, Chandra N, Johnson E, et al: Failure of sodium bicarbonate to improve resuscitation from ventricular fibrillation in dogs. Circulation 74:IV75-IV79, 1986.

    46. Nakakimura K, Fleischer JE, Drummond JC, et al: Glucose administration before cardiac arrest worsens neurologic outcome in cats. Anesthesiology 72:1005-1011, 1990.

    47. Steingrub JS, Mundt DJ: Blood glucose and neurologic outcome with global brain ischemia. Crit Care Med 24:802-806, 1996.

    48. Niemann JT, Stratton SJ: Endotracheal versus intravenous epinephrine and atropine in out-of-hospital "primary" and postcountershock asystole. Crit Care Med 28:1815-1819, 2000.

    49. Niemann JT, Stratton SJ, Cruz B, Lewis RJ: Endotracheal drug administration during out-of-hospital resuscitation: Where are the survivors? Resuscitation 53:153-157, 2002.

    50. Quinton DN, O'Byrne G, Aitkenhead AR: Comparison of endotracheal and peripheral intravenous adrenaline in cardiac arrest: Is the endotracheal route reliable? Lancet 1:828-829, 1987.

    51. Orlowski JP, Porembka DT, Gallagher JM, et al: Comparison study of intraosseous, central intravenous, and peripheral intravenous infusions of emergency drugs. Am J Dis Child 144:112-117, 1990.

    52. Spivey WH, Crespo SG, Fuhs LR, Schoffstall JM: Plasma catecholamine levels after intraosseous epinephrine administration in a cardiac arrest model. Ann Emerg Med 21:127-131, 1992.

    53. Sabin HI, Coghill SB, Khunti K, McNeill GO: Accuracy of intracardiac injections determined by a post-mortem study. Lancet 2:1054-1055, 1983.

    54. Grundler WG, Weil MH, Miller JM, Rackow EC: Observations on colloid osmotic pressure, hematocrit, and plasma osmolality during cardiac arrest. Crit Care Med 13:895-896, 1985.

    55. Jehle D, Fiorello AB, Brader E, et al: Hemoconcentration during cardiac arrest and CPR. Am J Emerg Med 12:524-526, 1994.

    56. Ditchey RV, Lindenfeld J: Potential adverse effects of volume loading on perfusion of vital organs during closed-chest resuscitation. Circulation 69:181-189, 1984.

    57. Gentile NT, Martin GB, Appleton TJ, et al: Effects of arterial and venous volume infusion on coronary perfusion pressures during canine CPR. Resuscitation 22:55-63, 1991.

    58. Voorhees WD, Ralston SH, Kougias C, Schmitz PM: Fluid loading with whole blood or Ringer's lactate solution during CPR in dogs. Resuscitation 15:113-123, 1987.

    59. Fischer M, Hossmann KA: Volume expansion during cardiopulmonary resuscitation reduces cerebral no-reflow. Resuscitation 32:227-240, 1996.

    60. Fischer M, Dahmen A, Standop J, et al: Effects of hypertonic saline on myocardial blood flow in a porcine model of prolonged cardiac arrest. Resuscitation 54:269-280, 2002.

    61. Ausina A, Baguena M, Nadal M, et al: Cerebral hemodynamic changes during sustained hypocapnia in severe head injury: Can hyperventilation cause cerebral ischemia? Acta Neurochir Suppl (Wien) 712-, 1998.

    62. Nagel EL, Fine EG, Krischer JP, Davis JH: Complications of CPR. Crit Care Med 9:424, 1981.

    63. Jorgensen EO, Holm S: The natural course of neurological recovery following cardiopulmonary resuscitation. Resuscitation 36:111-122, 1998.

    64. Allen CH, Ward JD: An evidence-based approach to management of increased intracranial pressure. Crit Care Clin 14:485-495, 1998.

    65. Safar P, Xiao F, Radovsky A, et al: Improved cerebral resuscitation from cardiac arrest in dogs with mild hypothermia plus blood flow promotion. Stroke 27:105-113, 1996.

    References »

    NEXT: Cardiopulmonary Cerebral Resuscitation: Techniques


    Did you know... Hydrogen peroxide solutions with concentrations >3% can be corrosive to the gastrointestinal mucosa and, therefore, should never be used to induce vomiting.Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More